biostudies-literatureUnknown25(1)Beau-Faller MFrenchNational Cancer InstituteLigue Nationale Contre le Cancer<h4>Background</h4>There is scarce data available about epidermal growth factor receptor (EGFR) mutations other than common exon 19 deletions and exon 21 (L858R) mutations.<h4>Patients and methods</h4>EGFR exon 18 and/or exon 20 mutations were collected from 10 117 non-small-cell lung cancer (NSCLC) samples analysed at 15 French National Cancer Institute (INCa)-platforms of the ERMETIC-IFCT network.<h4>Results</h4>Between 2008 and 2011, 1047 (10%) samples were EGFR-mutated, 102 (10%) with rare mutations: 41 (4%) in exon 18, 49 (5%) in exon 20, and 12 (1%) with other EGFR mutations. Exon 20 mutations were related to never-smoker status, when compared with exon 18 mutations (P < 0.001). Median overall survival (OS) of metastatic disease was 21 months [95% confidence interval (CI) 12-24], worAnnals of oncology : official journal of the European Society for Medical Oncology126-31https://www.ebi.ac.uk/biostudies/studies/S-EPMC3868323biostudies-literatureRare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network.PMC3868323Nanni-Metellus ILacroix LBlons HLacave REscande FPrim NBieche IRouquette IPretet JLVoegeli ACBaudrin LMorin FBesse BZalcman GSolassol Jde Fraipont Fde Cremoux PCayre ALizard STomasini PCadranel JBeau-Faller MQuoix EFavre-Guillevin ELegrain MRuppert AMWislez MfalseRare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network.<h4>Background</h4>There is scarce data available about epidermal growth factor receptor (EGFR) mutations other than common exon 19 deletions and exon 21 (L858R) mutations.<h4>Patients and methods</h4>EGFR exon 18 and/or exon 20 mutations were collected from 10 117 non-small-cell lung cancer (NSCLC) samples analysed at 15 French National Cancer Institute (INCa)-platforms of the ERMETIC-IFCT network.<h4>Results</h4>Between 2008 and 2011, 1047 (10%) samples were EGFR-mutated, 102 (10%) with rare mutations: 41 (4%) in exon 18, 49 (5%) in exon 20, and 12 (1%) with other EGFR mutations. Exon 20 mutations were related to never-smoker status, when compared with exon 18 mutations (P < 0.001). Median overall survival (OS) of metastatic disease was 21 months [95% confidence interval (CI) 12-24], wor2014-01-01T00:00:00Z2014 Jan2026-04-14T17:14:46.034Z2025-07-28T03:04:09.49ZS-EPMC38683232428502110.1093/annonc/mdt418